No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305

INTRODUCTION: Tenofovir (TDF)-containing PrEP is effective for HIV prevention, but its effect on health-related quality of life (QOL) is unknown. Using data from HPTN 069/ACTG A5305, a randomized study of potential PrEP regimens comparing maraviroc alone, or together with TDF or emtricitabine (FTC),...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapadia, Shashi N., Wu, Chunyuan, Mayer, Kenneth H., Wilkin, Timothy J., Amico, K. Rivet, Landovitz, Raphael J., Andrade, Adriana, Chen, Ying Q., Chege, Wairimu, McCauley, Marybeth, Gulick, Roy M., Schackman, Bruce R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306196/
https://www.ncbi.nlm.nih.gov/pubmed/30586364
http://dx.doi.org/10.1371/journal.pone.0206577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306196/
https://www.ncbi.nlm.nih.gov/pubmed/30586364
http://dx.doi.org/10.1371/journal.pone.0206577

Ejemplares similares